Absci Corporation Appoints Mary Szela to Board of Directors

Published: 2025-07-07 09:05:34 ET ABSI

Published on 07/07/2025 at 09:05

Absci announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. Ms. Szela brings a wealth of board-level expertise including her service on the boards of Prometheus Biosciences, which was acquired by Merck for $10.8B based on its lead TL1A program, Kura Oncology, and Novo Nordisk.

She currently serves as Chief Executive Officer, President, and Director of TriSalus Life Sciences. Previously, Ms. Szela received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago. Ms. Szela joins Absci as the company expands and accelerates development of its AI-designed pipeline programs. This includes ABS-101, an anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD) with Phase 1 interim data expected later this year, and ABS-201, an anti-prolactin receptor antibody for the treatment of androgenetic alopecia anticipated to enter the clinic in early 2026.